Sfoglia per Rivista  HAEMATOLOGICA

opzioni
Vai a: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Mostra risultati da 1 a 11 di 11
Titolo Data di pubblicazione Autore(i) File
A PRACTICAL APPROACH TO THERAPEUTIC DRUG MONITORING OF IMATINIB IN PATIENTS AFFECTED BY CHRONIC MYELOID ELEUKEMIA. THE TIKLET PROTOCOL. 1-gen-2012 Galimberti, Sara; Polillo, M; Baratè, C; Guerrini, Francesca; Cervetti, G; Capecchi, M; Danesi, Romano; Petrini, Mario; DI PAOLO, Antonello
BONE MARROW CYTOKINE CHANGES DURING TREATMENT WITH LENALIDOMIDE IN LOW AND INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES WITH DEL(5Q) 1-gen-2010 Oliva, En; Ronco, F; Cuzzola, M; Alimena, G; Morabito, F; Aloe Spiriti, Ma; Galimberti, Sara; Cortelezzi, A; Specchia, G; Poloni, A; Ghio, R; Breccia, M; Finelli, C; Iacopino, P; D'Errigo, Mg; Laganà, C; Latagliata, R; Nobile, F.
Combined unfavourable polymorphisms ofhOCT1 and ABCG2 are responsible for delayed complete cytogenetic response during imatinib treatment. 1-gen-2014 Galimberti, Sara; Galeotti, L; Ceccherini, F; Laurino, M; Cornolti, Fulvio; Guerrini, Francesca; Ciabatti, Elena; Grassi, S; Baratè, C; Fontanelli, G; Barsotti, S; Ricci, F; Arici, Roberta; Petrini, Mario; Polillo, Ml; DI PAOLO, Antonello
Expression of MDR1, MRP, TOPOISOMERASE-IIa, TOPOISOMERASE-IIb and GSTp in acute leukemias. 1-gen-1996 Galimberti, Sara; Testi, Rossana; Mattii, Letizia; Di Simone, D; Petrini, Mario
THE HOCT1/ABCB1 DIPLOTYPE IS ASSOCIATED WITH COMPLETE CYTOGENETIC RESPONSE AND TOLERABILITY TO IMATINIB IN PATIENTS AFFECTED BY CHRONIC MYELOID LEUKEMIA 1-gen-2016 Galimberti, Sara; Galeotti, L.; Ceccherini, F.; Domingo, D.; Laurino, M.; Barate, C; Ricci, F; Grassi, S.; Guerrini, F; Fava, C; D'Avolio, A; Cervetti, G.; Fontanelli, G.; Saglio, G.; Cornolti, Fulvio; Petrini, Mario; Arrigoni, E; DI PAOLO, Antonello
Immune Reconstitution after Allogeneic Stem Cell Transplantation: a Pilot Flow-Cytometry Study for T-Cell Sub-Populations 1-gen-2015 Iovino, L; Orciuolo, E.; Grassi, A.; Buda, G.; Caracciolo, F.; Carulli, G.; Mazziotta, F.; Sammuri, P.; Traverso, Ginevra; Galimberti, S.; Benedetti, E.; Petrini, M.
Inhibitors of A Disintegrin And Metalloproteinases-10 reduce Hodgkin lymphoma cell growth in 3D microenvironments and enhance brentuximab-vedotin effect 1-gen-2022 Pece, Roberta; Tavella, Sara; Costa, Delfina; Varesano, Serena; Camodeca, Caterina; Cuffaro, Doretta; Nuti, Elisa; Rossello, Armando; Alfano, Massimo; D'Arrigo, Cristina; Galante, Denise; Ravetti, Jean-Louis; Gobbi, Marco; Tosetti, Francesca; Poggi, Alessandro; Zocchi, Maria Raffaella
ORAL CYCLOPHOSPHAMIDE AND RITUXIMAB IN THE TREATMENT OF MARGINAL ZONE LYMPHOMA 1-gen-2011 Orciuolo, E; Ghio, F; Buda, G; Galimberti, Sara; Pelosini, M; Cecconi, N; Cervetti, G; Petrini, Mario
RITUXIMAB PLUS HYPERCVAD ALTERNATING WITH HIGH DOSE METHOTREXATE AND CYTARABINE (R-HCVAD-AM) FOR PATIENTS WITH NEWLY DIAGNOSED MANTLE CELL LYMPHOMA (MCL). A MULTICENTER TRIAL FROM GISL 1-gen-2011 Merli, F; Luminari, S; Ilariucci, F; Petrini, Mario; Visco, C; Ambrosetti, A; Stelitano, C; Caracciolo, F; Di Renzo, N; Angrilli, F; Carella, Am; Capodanno, I; Barbolini, E; Galimberti, Sara; Federico, M.
SAFETY AND EFFICACY OF 90 Y IBRITUMUMAB TIUXETAN (ZEVALIN) FOR UNTREATED FOLLICULAR NON HODGKIN'S LYMPHOMA (FL) PATIENTS. ITALIAN MULTICENTRIC TRIAL. 1-gen-2011 Pica, Gm; Nati, S; Vitolo, U; Botto, B; Galimberti, Sara; Zinzani, Pl; Cascavilla, N; Petrini, Mario; Carella, A. M.
Targeting GLUT1 in acute myeloid leukemia to overcome cytarabine resistance 1-gen-2021 Abacka, H.; Hansen, J. S.; Huang, P.; Venskutonyte, R.; Hyrenius-Wittsten, A.; Poli, G.; Tuccinardi, T.; Granchi, C.; Minutolo, F.; Hagstrom-Andersson, A. K.; Lindkvist-Petersson, K.
Mostra risultati da 1 a 11 di 11
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile